Navigation Links
Genmab Reaches Milestone in Ofatumumab Collaboration
Date:6/30/2008

Summary: Genmab has Reached a Milestone in its Ofatumumab Collaboration

With GlaxoSmithKline

COPENHAGEN, June 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 29 million (approximately USD 6 million) was triggered by treatment of the first patient participating in the Phase II study of ofatumumab for the treatment of relapsing remitting multiple sclerosis (RRMS).

"Our collaboration with GSK continues to progress as both companies work towards providing new treatment options for patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We are pleased to begin treating patients in the first study of ofatumumab in RRMS, an unpredictable and debilitating disease."

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different from the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GSK.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact:

Helle Husted, Sr. Director, Investor Relations,

T: +45-33-44-77-30,

M: +45-25-27-47-13,

E: hth@genmab.com


'/>"/>
SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
2. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
3. Genmab Announces Updates on Phase III Cancer Studies
4. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
5. Bionomics Achieves US$1 Million Milestone Payment from Genmab
6. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
7. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
8. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
9. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
10. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
11. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mosaic Life Care, based in St. Joseph, Missouri , has selected ... 58 clinics, located in 22 cities, and its flagship St. Joseph Medical Center. ... delivery of health care to its patients, including the insurance, billing and collections processes. ... ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... , March 23, 2017 ... research report created through extensive primary research (inputs ... the report aims to present the analysis of ... of Procedure (Replacement and Repair); Replacement Procedure By ... Repair By Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter ...
(Date:3/23/2017)... , March 23, 2017 ... and Healthcare disease pipeline guide Primary Hyperoxaluria - ... the Primary Hyperoxaluria (Genito Urinary System And Sex ... rare condition characterized by recurrent kidney and bladder ... substance called oxalate. Symptoms include blood in the ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Oklahoma City Convention Center at 10 North Broadway Avenue, will be an educational ... of relevant, practical instruction in the management of chronic pain. , Oklahoma is ...
(Date:3/23/2017)... OH (PRWEB) , ... March ... ... insurance and financial services firm serving the families and businesses of the ... community enrichment program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... investment in Los Angeles based healthcare technology company California Healthcom Group (CHG). ... the US, and healthcare arena. With headquarters in California, CHG is a growing, ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... solution that enables organizations to easily reprint customer invoices, bills, statements and other ... all of the steps needed to retrieve and print the documents and batch ...
Breaking Medicine News(10 mins):